One-Shot cancer treatment trial seeks to reprogram immune system from within
NCT ID NCT07485504
Summary
This early-stage study is testing the safety of an experimental therapy called DIT101 for adults whose blood cancers have returned or not responded to standard treatments. DIT101 is a one-time infusion designed to instruct the body's own immune system to create cancer-fighting cells, aiming to control the disease. Unlike some other advanced cell therapies, this approach does not require removing and modifying a patient's cells in a lab first.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences)
Tianjin, China
Conditions
Explore the condition pages connected to this study.